Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation

NCT01527045 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01527045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01527045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
September 25, 2012
Completion date
April 30, 2019
Enrollment
47 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive non-hodgkin lymphoma, blasts under 5 percent of bone marrow nucleated cells, chronic lymphocytic leukemia, loss of chromosome 17p, myelodysplastic/myeloproliferative neoplasm, non-hodgkin lymphoma, prolymphocytic leukemia, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent aggressive adult non-hodgkin lymphoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent chronic lymphocytic leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent diffuse large b-cell lymphoma, recurrent hodgkin lymphoma, recurrent mantle cell lymphoma, recurrent non-hodgkin lymphoma, recurrent plasma cell myeloma, recurrent small lymphocytic lymphoma, waldenstrom macroglobulinemia